Freedom Biosciences Emerges From Stealth With $10.5 Million Seed Financing To Develop Next-Generation Ketamine And Psychedelic-Based Mental Health Treatments

Aug 23, 2022•almost 3 years ago

Amount Raised

$10.5 Million

Round Type

seed

San FranciscoBiotechnology

Description

Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory programs.

Company Information

Company

Freedom Biosciences

Location

San Francisco, California, United States

About

Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics. The company was co-founded by Dr. John Krystal, Chair of the Department of Psychiatry at Yale University, and Dina Burkitbayeva, founder of PsyMed Ventures, alongside Hunter Bouchard and Morgan Springer. Freedom Biosciences launched from stealth in 2022 and is backed by MBX Capital, Village Global and PsyMed Ventures, among others. To learn more, visit: www.freedombio.co

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Freedom Biosciences Emerges From Stealth With $10.5 Million Seed Financing To Develop Next-Generation Ketamine And Psychedelic-Based Mental Health Treatments

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information